BACKGROUND: Transplantation of human skin on immunodeficient mice that support engraftment with functional human immune systems would be an invaluable tool for investigating mechanisms involved in wound healing and transplantation. Nonobese diabetic (NOD)-scid interleukin-2 gamma chain receptor (NSG) readily engraft with human immune systems, but human skin graft integrity is poor. In contrast, human skin graft integrity is excellent on CB17-scid bg (SCID.bg) mice, but they engraft poorly with human immune systems. METHODS: Human skin grafts transplanted onto immunodeficient NSG, SCID.bg, and other immunodeficient strains were evaluated for graft integrity, preservation of graft endothelium, and their ability to be rejected after engraftment of allogeneic peripheral blood mononuclear cells. RESULTS: Human skin transplanted onto NSG mice develops an inflammatory infiltrate, consisting predominately of host Gr1(+) cells, that is detrimental to the survival of human endothelium in the graft. Treatment of graft recipients with anti-Gr1 antibody reduces this cellular infiltrate, preserves graft endothelium, and promotes wound healing, tissue development, and graft remodeling. Excellent graft integrity of the transplanted skin includes multilayered stratified human epidermis, well-developed human vasculature, human fibroblasts, and passenger leukocytes. Injection of unfractionated, CD4 or CD8 allogeneic human peripheral blood mononuclear cell induces a rapid destruction of the transplanted skin graft. CONCLUSIONS: NSG mice treated with anti-Gr1 antibody provide a model optimized for both human skin graft integrity and engraftment of a functional human immune system. This model provides the opportunity to investigate mechanisms orchestrating inflammation, wound healing, revascularization, tissue remodeling, and allograft rejection and can provide guidance for improving outcomes after clinical transplantation.
BACKGROUND: Transplantation of human skin on immunodeficientmice that support engraftment with functional human immune systems would be an invaluable tool for investigating mechanisms involved in wound healing and transplantation. Nonobese diabetic (NOD)-scid interleukin-2 gamma chain receptor (NSG) readily engraft with human immune systems, but human skin graft integrity is poor. In contrast, human skin graft integrity is excellent on CB17-scid bg (SCID.bg) mice, but they engraft poorly with human immune systems. METHODS:Human skin grafts transplanted onto immunodeficient NSG, SCID.bg, and other immunodeficient strains were evaluated for graft integrity, preservation of graft endothelium, and their ability to be rejected after engraftment of allogeneic peripheral blood mononuclear cells. RESULTS:Human skin transplanted onto NSG mice develops an inflammatory infiltrate, consisting predominately of host Gr1(+) cells, that is detrimental to the survival of human endothelium in the graft. Treatment of graft recipients with anti-Gr1 antibody reduces this cellular infiltrate, preserves graft endothelium, and promotes wound healing, tissue development, and graft remodeling. Excellent graft integrity of the transplanted skin includes multilayered stratified human epidermis, well-developed human vasculature, human fibroblasts, and passenger leukocytes. Injection of unfractionated, CD4 or CD8 allogeneic human peripheral blood mononuclear cell induces a rapid destruction of the transplanted skin graft. CONCLUSIONS: NSG mice treated with anti-Gr1 antibody provide a model optimized for both human skin graft integrity and engraftment of a functional human immune system. This model provides the opportunity to investigate mechanisms orchestrating inflammation, wound healing, revascularization, tissue remodeling, and allograft rejection and can provide guidance for improving outcomes after clinical transplantation.
Authors: Michelle R Simpson-Abelson; Gregory F Sonnenberg; Hiroshi Takita; Sandra J Yokota; Thomas F Conway; Raymond J Kelleher; Leonard D Shultz; Maurice Barcos; Richard B Bankert Journal: J Immunol Date: 2008-05-15 Impact factor: 5.422
Authors: Nicolas Legrand; Alexander Ploss; Rudi Balling; Pablo D Becker; Chiara Borsotti; Nicolas Brezillon; Jennifer Debarry; Ype de Jong; Hongkui Deng; James P Di Santo; Stephanie Eisenbarth; Elizabeth Eynon; Richard A Flavell; Carlos A Guzman; Nicholas D Huntington; Dina Kremsdorf; Michael P Manns; Markus G Manz; Jean-Jacques Mention; Michael Ott; Chozhavendan Rathinam; Charles M Rice; Anthony Rongvaux; Sean Stevens; Hergen Spits; Hélène Strick-Marchand; Hitoshi Takizawa; Anja U van Lent; Chengyan Wang; Kees Weijer; Tim Willinger; Patrick Ziegler Journal: Cell Host Microbe Date: 2009-07-23 Impact factor: 21.023
Authors: Nancy C Kirkiles-Smith; Martha J Harding; Benjamin R Shepherd; Stacey A Fader; Tai Yi; Yinong Wang; Jennifer M McNiff; Edward L Snyder; Marc I Lorber; George Tellides; Jordan S Pober Journal: Transplantation Date: 2009-01-27 Impact factor: 4.939
Authors: Matthias Nahrendorf; Filip K Swirski; Elena Aikawa; Lars Stangenberg; Thomas Wurdinger; Jose-Luiz Figueiredo; Peter Libby; Ralph Weissleder; Mikael J Pittet Journal: J Exp Med Date: 2007-11-19 Impact factor: 14.307
Authors: Omar H Khalaf; Sankar P Chaki; Daniel G Garcia-Gonzalez; Thomas A Ficht; Angela M Arenas-Gamboa Journal: Infect Immun Date: 2019-05-21 Impact factor: 3.441
Authors: Sara L Sinicropi-Yao; Joseph M Amann; David Lopez Y Lopez; Ferdinando Cerciello; Kevin R Coombes; David P Carbone Journal: J Thorac Oncol Date: 2018-11-05 Impact factor: 15.609
Authors: Michael A Brehm; Waldemar J Racki; Jean Leif; Lisa Burzenski; Vishnu Hosur; Amber Wetmore; Bruce Gott; Mary Herlihy; Ronald Ignotz; Raymond Dunn; Leonard D Shultz; Dale L Greiner Journal: Blood Date: 2012-01-12 Impact factor: 22.113
Authors: Esther M Yoo; Kham R Trinh; Danh Tran; Alex Vasuthasawat; Juan Zhang; Bao Hoang; Alan Lichtenstein; Sherie L Morrison Journal: J Interferon Cytokine Res Date: 2014-10-29 Impact factor: 2.607